EU ‘Structured Dialog’ Offers Opportunity To Secure Supply
Industry Calls For Policies, Investment And Regulation To Support Manufacturing
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
You may also be interested in...
The European Commission has launched the process for reshaping and addressing the long-standing weakness in the EU’s pharmaceutical legislation. It has listed in a roadmap the issues it wants to address as it considers policy options for reforms.
Ahead of an upcoming European Council meeting covering the EU’s industrial policy and ongoing response to the COVID-19 pandemic, Medicines for Europe has set out what it sees as key policy objectives to consider.
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.